Targeting Anemia in Patients with Lung Cancer

Slides:

Advertisements

Similar presentations

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled.

Advertisements

A Hole in the Heart Journal of Thoracic Oncology

Su K. Metcalfe, MD, MPH, Michael T

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled.

Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Electronic Updates for JTO Readers

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment.

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer:

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree,

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

George Blumenschein, MD, John V. Heymach, MD, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer Taofeek K. Owonikoko, MD, Madhusmita.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

A Hole in the Heart Journal of Thoracic Oncology

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY ) Versus Pemetrexed in Patients with Non-small Cell.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Genetic Changes in Squamous Cell Lung Cancer: A Review

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

European Lung Cancer Conference (ELCC) 2016 Organisation

S-1 Treatment for Chemorefractory Thymic Carcinoma

Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development.

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

Targeting Anemia in Patients with Lung Cancer Jeffrey Crawford, MD, Paris A. Kosmidis, MD, Fred R. Hirsch, MD, PhD, Corey J. Langer, MD Journal of Thoracic Oncology Volume 1, Issue 7, Pages 716-725 (September 2006) DOI: 10.1016/S1556-0864(15)30388-9 Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Frequency of anemia by cancer treatment during the European Cancer Anaemia Survey.27 CT, chemotherapy; RT, radiation therapy. *Analysis population, n = 1900 (missing data for two patients). Combination CT/RT refers to administration of CT and RT at different times (i.e., not concomitantly). Journal of Thoracic Oncology 2006 1, 716-725DOI: (10.1016/S1556-0864(15)30388-9) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Mean change in Linear Analog Scale Assessment (LASA) scores from baseline to final measurement in patients with lung cancer.14 QOL, quality of life. *p < 0.0001 versus baseline (adjusted for multiple comparisons). Adapted from Clinical Lung Cancer, volume 3. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Pages 180–190. ©Copyright 2002. Used with permission from: Cancer Information Group. Journal of Thoracic Oncology 2006 1, 716-725DOI: (10.1016/S1556-0864(15)30388-9) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Treatment schema of a randomized, multicenter study evaluating the safety and efficacy of immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with NSCLC receiving first-line chemotherapy.37 NSCLC, non-small cell lung cancer; SC, subcutaneously; QW, once weekly; Hb, hemoglobin. Journal of Thoracic Oncology 2006 1, 716-725DOI: (10.1016/S1556-0864(15)30388-9) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Linear Analog Scale Assessment (LASA) Overall QOL scores during a randomized, multicenter study evaluating the efficacy of immediate versus delayed treatment with epoetin alfa in patients with NSCLC receiving first-line chemotherapy.37 QOL, quality of life; NSCLC, non-small cell lung cancer. *Includes all control patients, including 48 patients who received epoetin alfa because Hb decreased to less than 10 g/dL. †p = 0.01 versus the immediate group. Journal of Thoracic Oncology 2006 1, 716-725DOI: (10.1016/S1556-0864(15)30388-9) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions